Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: Screening and prognostic impact of c-KIT mutations

Leukemia

Volumn 28, Issue 5, 2014, Pages 1132-1134

  Manara, E ^a   Bisio, V ^a   Masetti, R ^b   Beqiri, V ^a   Rondelli, R ^b   Menna, G ^c   Micalizzi, C ^d   Santoro, N ^e   Locatelli, F ^f   Basso, G ^a   Pigazzi, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Hospital Pausilipon   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e POLICLINICO   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CORE BINDING FACTOR; CORE BINDING FACTOR BETA; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CODON; CONTROLLED STUDY; CORE BINDING FACTOR BETA GENE; CORE BINDING FACTOR GENE; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; EXON; FEMALE; GENE; GENE AMPLIFICATION; GENE DUPLICATION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC SCREENING; HUMAN; INCIDENCE; INFANT; LETTER; MAJOR CLINICAL STUDY; MALE; MYH11 GENE; ONCOGENE C KIT; OVERALL SURVIVAL; POINT MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RUNX1T1 GENE; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME;

CORE BINDING FACTORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84899904638     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.339     Document Type: Letter

References (15)

1. Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R. et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 2013; 27: 1891-1901.
2. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K. et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006; 107: 1791-1799.
3. Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A. et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): A study of the German-Austrian AML Study Group (AMLSG). Blood 2013; 121: 170-177.
4. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y. et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010; 115: 2372-2379.
5. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S. et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005; 19: 1536-1542.
6. Shih LY, Liang DC, Huang CF, Chang YT, Lai CL, Lin TH. et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 2008; 22: 303-307.
7. Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M. et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group. Blood 2006; 107: 1806-1809.
8. Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F. et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013; 122: 170-178.
9. Kohl TM, Schnittger S, Ellwart JW, Hiddemann W, Spiekermann K. KIT exon 8 mutations associated with core-binding factor (CBF)-Acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005; 105: 3319-3321.
10. Downing JR. The core-binding factor leukemias: Lessons learned from murine models. Curr Opin Genet Dev 2003; 13: 48-54.
11. Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC. et al. Acute myeloid leukemia with the 8q22;21q22 translocation: Secondary mutational events and alternative t(8;21) transcripts. Blood 2007; 110: 799-805.
12. Muller AM, Duque J, Shizuru JA, Lubbert M. Complementing mutations in core binding factor leukemias: From mouse models to clinical applications. Oncogene 2008; 27: 5759-5773.
13. Grisolano JL, O?Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2003; 100: 9506-9511.
14. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N. et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from Study AML-BFM 2004. Blood 2003; 122: 37-43.
15. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A. et al. Second induction with high-dose cytarabine and mitoxantrone: Different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011; 118: 5409-5415.